Neurizon Therapeutics LimitedASX: NUZ

Neurizon Commences Initiatives to Lift Clinical Hold

· Issued by Neurizon Therapeutics Limited

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The company is in ongoing communication with the US FDA and has submitted a formal request for advice on necessary pharmacokinetic studies. Neurizon plans to proactively commence these studies to generate additional data, which is expected to take around four months to complete.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Neurizon Therapeutics Limited on 6ix

Earlier from Neurizon Therapeutics

Later from Neurizon Therapeutics

All Neurizon Therapeutics news releases